Duchenne muscular dystrophy (DMD) is a severe striated muscle disease due to the absence of dystrophin. Dystrophin deficiency results in dysfunctional sodium channels and conduction abnormalities in hearts of mdx mice. Disease progression in the mdx mouse only modestly reflects that of DMD patients, possibly due to utrophin up-regulation. Here, we investigated mice deficient in both dystrophin and utrophin [double knockout (DKO)] to assess the role of utrophin in the regulation of the cardiac sodium channel (Na v 1.5) in mdx mice.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder affecting 1/3500 males and is currently the most severe dystrophinopathy. 1 The disease results from the absence of dystrophin, a protein mainly expressed in striated muscle cells. 2 The main clinical manifestations of dystrophinopathies are loss of skeletal and cardiac muscle strength and elasticity and respiratory insufficiency. 3 Cardiomyopathies are observed in 90% of dystrophic patients, and 20% die from cardiac complications. 4 Dystrophin, a 427 kDa cytoskeletal protein, plays a major structural role in muscle cells. It links the cytoskeleton to the extracellular matrix through the binding of the N-terminus to actin and the C-terminus to the glycoprotein complex at the sarcolemma, forming a dystrophin multi-protein complex (DMC). 5 The mdx mouse, which lacks dystrophin, is the classical animal model of DMD. 6 The phenotype of mdx mice, however, does not fully mimic that of dystrophic patients. Contrary to human carriers of mutations causing full length dystrophin deletions, mdx mice have a nearly normal lifespan and display different patterns of distribution and severity of fibrosis. 7 Utrophin, a homologue of dystrophin encoded by an autosomic gene, is up-regulated in dystrophic muscle, which may partially compensate for the lack of dystrophin in mdx mice, providing an explanation to their milder phenotype. 8 Similar to dystrophin, utrophin is a member of the DMC and binds to syntrophins, 9 which are adapter proteins between different components of the DMC. 10 Syntrophins have been shown to mediate the link between the cardiac voltage-gated sodium channel Na v 1.5 and dystrophin. 11, 12 The Na v 1.5 channel plays a key role in the depolarization phase of the cardiac action potential (AP) as well as the propagation of the electrical impulse. 13 The primordial role of Na v 1.5 for normal cardiac function is emphasized by hundreds of mutations found in its gene (SCN5A), which have been linked to cardiac diseases such as type-3 long QT syndrome, Brugada syndrome, and dilated cardiomyopathy. 14 In a previous study, 11 our group showed that dystrophin plays an important role in the functional expression of the cardiac sodium channel. Na v 1.5 protein levels and the sodium current were decreased in mdx5cv mice, an alternative mouse strain of mdx which also lacks full length dystrophin. Tinsley et al. 15 were the first to suggest a compensatory role of utrophin in the absence of dystrophin. In the present study, we investigated this potential role of utrophin in the regulation of the cardiac sodium channel in mdx mice. We first describe a syntrophin-mediated interaction between Na v 1.5 and utrophin. Next, mice deficient for both dystrophin and utrophin [double knockout (DKO)] were used to assess the role of utrophin in the regulation of Na v 1.5 in mice lacking dystrophin only (mdx). Sodium channel protein levels and sodium current density (I Na ) were decreased in DKO mice compared with mdx mice, which was reflected in a significant slowing of maximal upstroke velocity of the AP. These results reveal that utrophin plays a central role in the regulation of Na v 1.5 in mdx mice and provide additional evidence in support of therapeutic strategies aimed at utrophin up-regulation in DMD patients.
Methods
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996). All animal handling was performed with the permission from the Cantonal Veterinary Administration and according to the Swiss Federal Animal Protection law.
Animals
C57BL/6Ros-5Cv (mdx5cv), mdx, and their control C57BL/10 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Control C57BL/6J mice were purchased from Janvier (Le Genest, St Isle, France). Mdx/DKO mice were obtained from the group of Pr. K.E. Davies (University of Oxford, UK). Male mice, 8 -10 weeks of age, were used in this study.
Western blots
HEK293 cells or homogenized whole mouse heart was lysed in 1.0 mL of lysis buffer [50 mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 10% glycerol, 1% Triton, 1 mmol/L EGTA supplemented with 10 mmol/L N-ethyl maleimide and protease inhibitors (Roche, Basel, Switzerland)]. Protein concentrations were determined by performing Bradford assays (Coo protein dosage kit; Interchim, Montluçon, France). About 40 mg of protein was loaded onto sodium dodecyl sulphate (SDS) -polyacrylamide gel electrophoresis (PAGE). Protein transfer was performed using the dry system transfer i-blot from Invitrogen (Basel, Switzerland). Immunoblotting was performed using the snap-id system of Millipore (Zug, Switzerland). Detection was achieved using the LICOR systemw, and band intensity was quantified with Odyssey software (LICOR, Lincoln, Nebraska, USA). 'Edge effects' observed with high-molecular-weight proteins were verified to avoid modifying quantification by loading samples on different SDS -PAGE gels (homemade or Invitrogen pre-cast gel). Despite the presence of edge effects on some gels, values of quantification were unchanged.
Immunoprecipitation studies
About 1 mg of HEK293 cell lysate was incubated for 2 h at 48C with the appropriate antibody cross-linked to agarose beads using the direct immunoprecipitation kit from Pierce (Lausanne, Switzerland), according to manufacturer's instructions. The beads were washed three times with lysis buffer, and the immunoprecipitated fractions were analysed by western blot.
Pull-down assays
About 1 mg of total protein was added to 50 mg of glutathione S-transferase (GST)-Na v 1.5 C-terminus beads and incubated for 2 h at 48C. After washing the beads three times with lysis buffer, precipitated proteins were eluted with sampling buffer (Invitrogen) and analysed by western blot.
Membrane preparation
Mouse ventricular tissue was homogenized in homogenization buffer containing 50 mmol/L Tris -HCl, pH ¼ 7.5, 150 mmol/L NaCl, 10 mmol/L N-ethyl maleimide and protease inhibitors (Roche). The homogenate was centrifuged for 15 min at 1000 g to pellet debris. The supernatant was collected and centrifuged at 48C for 45 min at 50 000 g. The pellet was resuspended in the homogenization buffer supplemented with 1% Triton and analysed by western blot.
Isolation of mouse ventricular myocytes
Single cardiomyocytes were isolated according to a modified procedure of established enzymatic methods. 11 See Supplementary material online for details.
INa recordings
The whole-cell configuration of the patch-clamp technique was used to record I Na , as described previously. 11 Details are available in Supplementary material online.
AP recordings
Trains of APs were recorded in the whole-cell configuration of the patchclamp technique, elicited at 0. 
Statistical analyses
Data are represented as mean values + SEM. Statistical tests applied are described in the legends of the different experiments.
Results
3.1 Na v 1.5 interacts with utrophin via syntrophin proteins Na v 1.5 has been previously shown to interact indirectly with dystrophin and the DMC via syntrophin proteins. 11 The direct interaction between Na v 1.5 and syntrophins takes place at the last three Cterminal amino acids (SIV) of Na v 1.5, a PDZ domain-binding motif. 12 Utrophin, a homologue protein of dystrophin, is also present in the DMC 16 and was similarly shown to interact with syntrophins. We used HEK293 cells to investigate whether an interaction between Na v 1.5 and utrophin exists as they have a robust endogenous expression of utrophin, but not dystrophin (see Supplementary material online, Figure S1 ). HEK293 cells were transiently transfected with wild-type (WT) Na v 1.5 or Na v 1.5 DSIV, the WT channel with the three last amino acids deleted. Na v 1.5 was immunoprecipitated, yielding the co-immunoprecipitated fraction with antibodies against syntrophin and utrophin. We found that both syntrophin and utrophin interact with the WT channel ( Figure 1A ) and that these interactions are abolished when Na v 1.5 DSIV is immunoprecipitated. This finding confirms that the interaction occurs via the SIV motif of Na v 1.5. In addition, utrophin was identified by mass spectrometry in the co-immunoprecipitated fraction of Na v 1.5 from HEK293 cells (data not shown), confirming that the utrophin signal detected with the anti-utrophin antibody is not due to a cross-reaction with a homologous protein, such as dystrophin. Syntrophin proteins were then immunoprecipitated, yielding a co-immunoprecipitated fraction blotted with antibodies against Na v 1.5 and utrophin. Interactions between utrophin and syntrophins as well as those between syntrophins and Na v 1.5 were confirmed ( Figure 1A) . Moreover, the absence of Na v 1.5 DSIV in the co-immunoprecipitated fraction of syntrophins suggests that there is no direct interaction between Na v 1.5 and utrophin when the SIV sequence of the channel is absent. As shown in Figure 1B , we observed a significant reduction (23 + 6%) in the total Na v 1.5 DSIV protein level compared with Na v 1.5 WT, suggesting that the interaction between the channel and syntrophin proteins affects Na v 1.5 expression in HEK293 cells. To determine whether Na v 1.5 and utrophin interact in the mouse heart, where both utrophin and dystrophin are expressed, we used GST fusion proteins containing either the last 66 amino acids of the Na v 1.5 Cterminus or the corresponding Na v 1.5 C-terminus deleted for the SIV motif ( Figure 1C ). The GST fusion proteins were used to pulldown interacting proteins from WT C57BL/6J mouse heart lysates. As shown in Figure 1D , the WT C-terminus of Na v 1.5 interacts with both dystrophin and utrophin in the mouse heart, and these interactions are SIV motif-dependent. These findings suggest that utrophin, like dystrophin, may be an in vivo partner of the cardiac voltage-gated sodium channel Na v 1.5.
Utrophin is up-regulated in the hearts of mdx5cv dystrophin-deficient mice
Several studies have shown an up-regulation of utrophin in dystrophic skeletal and cardiac muscle of different species, including the human, mouse, and hamster. 17 -19 However, to our knowledge, the possible up-regulation of utrophin in cardiac muscle of mdx5cv mice had not yet been investigated. We set out to determine whether utrophin is up-regulated in the hearts of mdx5cv mice in which the cardiac sodium channel Na v 1.5 protein and current were shown to be reduced. 11 Western blot experiments show that mdx5cv mice exhibit an up-regulation of utrophin, as illustrated in Figure 2A . A 52 + 9% increase in utrophin expression was found in mdx5cv heart lysates ( Figure 2B ), similar to that found in mdx mice compared with C57BL/10 mice. 20 A down-regulation of syntrophin by 28 + 10% was concomitantly observed in mdx5cv mice when compared with control mice (Figure 2A and B), consistent with other studies showing that several proteins of the DMC, including syntrophin, were down-regulated in the absence of dystrophin. 21 3.3 Sodium current and Na v 1.5 protein are down-regulated in the hearts of DKO mice
Given that utrophin may be a partner of Na v 1.5 and is up-regulated in dystrophin-deficient mice, we assessed the consequence of utrophin deletion in mdx mice (DKO) on I Na . We previously found a 30% reduction in peak sodium current in cardiomyocytes of mdx5cv mice. 11 To confirm whether a decrease in I Na is also present in mdx mice, we performed patch-clamp experiments in the whole-cell configuration on freshly isolated cardiomyocytes. As shown in Figure 3A and B, I Na peak measured at 230 mV is reduced by 37 + 6% in mdx cardiomyocytes compared with the control C57BL/10 mice, confirming the common regulatory mechanism of I Na between these different mdx strains. Compared with littermate dystrophin-deficient mdx mice, a 41 + 5% reduction in I Na ( Figure 3A and B) was found in DKO mice, representing a 63 + 3% decrease in I Na when compared with C57BL/10 control mice ( Figure 3A and B). The difference in the peak I Na between the three groups was accompanied by small but statistically significant changes in the voltage dependence of activation and steady-state inactivation ( Figure 3C and Table 1 ). Quantification of Na v 1.5 protein levels by western blot in ventricular lysates of DKO and mdx mice revealed a statistically significant decrease in Na v 1.5 (25 + 8%) in DKO mice compared with mdx littermates ( Figure 4A and B), providing a potential explanation for the decrease in I Na . The amount of sodium channel proteins was also compared in membrane fractions from C57BL/10, mdx, and DKO hearts ( Figure 4C) . These experiments confirmed the statistically significant decrease in Na v 1.5 protein levels between C57BL/10 and mdx (17 + 4%) and also between mdx and DKO (14 + 7%). The decrease in the sodium channel in ventricular lysates was accompanied by a comparable reduction (42 + 12%) in syntrophin in DKO mice compared with mdx mice, illustrating the consequences of disorganization of the DMC on syntrophin expression ( Figure 4A and B).
Maximal AP upstroke velocity is reduced in DKO compared with mdx cardiomyocytes
Na v 1.5 plays a key role in the conduction of the cardiac electrical impulse and determines the upstroke velocity (dV m /dt) of the cardiac AP. Considering the strong reduction in the Na v 1.5 protein and current in DKO compared with mdx mice, we investigated whether these alterations were reflected in the APs recorded in freshly isolated ventricular myocytes from these two groups ( Figure 5A ). When analysing the AP upstrokes above threshold ( Figure 5B ), we found a significant reduction of about 30% in the maximal upstroke velocity in DKO cardiomyocytes compared with mdx (110.6 + 9.2 mV/ms in DKO and 151.8 + 9.4 mV/ms in mdx, Figure 5C ), consistent with the reduction in functional Na v 1.5 protein.
As shown in Figure 5D and E, no difference was found in either resting potential (270.6 + 0.8 and 272.2 + 0.5 mV in DKO and mdx, respectively) or AP amplitude (118.1 + 2.5 and 120.9 + 2.1 mV in DKO and mdx, respectively). Finally, although AP durations of 30 and 50% repolarization (APD30 and APD50) were unchanged, APD90 was slightly prolonged in DKO mice, although this difference was not significant ( Figure 5F ).
Discussion
In the present study, we observed that (i) utrophin indirectly binds to Na v 1.5 and this interaction is dependent on the binding of the Cterminal PDZ-binding domain motif SIV of the channel to syntrophins; (ii) utrophin is up-regulated in cardiac muscle of mdx5cv mice; (iii) cardiac sodium channel protein levels and current densities are strongly reduced in DKO mice compared with mdx mice; and (iv) loss of Na v 1.5 in DKO mice leads to slowing of the cardiac AP upstroke velocity.
Na v 1.5 and utrophin belong to the same multi-protein complex
The interaction between the cardiac voltage-gated sodium channel Na v 1.5 and syntrophin proteins has been described in previous studies. 11, 12 We demonstrated that this interaction occurs via the PDZ domain-binding motif (SIV) of Na v 1.5 and syntrophins. 11 There are five members (a 1 , b 1 , b 2 , g 1 , and g 2 ) of the syntrophin family that are differentially distributed in skeletal muscle and other tissues. 22, 23 In the heart, only three members have been found to be expressed, 24 with an unknown distribution. Gavillet et al. membrane and membrane-associated proteins to the DMC by binding to the C-terminus of dystrophin. The primary structures of the C-terminus of utrophin and dystrophin are very similar, 25 and there is evidence from in vitro and in vivo studies that utrophin can also interact with members of the DMC, such as b-dystroglycan, a-dystrobrevin-1, and syntrophins. 26, 27 In the heart, however, evidence of an utrophin-associated complex at the cellular or subcellular level has not yet been identified. We obtained evidence that utrophin, similar to dystrophin, could be an in vivo partner of Na v 1.5, even though we failed to demonstrate it in the mouse heart by co-immunoprecipitation experiments, despite testing many different protocols. We also showed that this indirect interaction is dependent on the direct interaction of the SIV domain of the channel with syntrophin. Although utrophin localization has been well characterized at the neuromuscular junction (NMJ), 28 very little is known about its cardiac subcellular localization and different studies published are controversial. 29 -31 The generation of two different strains of Regulation of Na v 1.5 by utrophin in mdx mice utrophin-deficient mice has revealed very subtle phenotypes at the NMJ, 32, 33 without any evidence of dystrophin up-regulation.
However, recent studies in vascular endothelial cells suggest that utrophin could be essential for the assembly of the DMC. 34 Although utrophin may play a minor role in the integrity of the DMC and the expression of functional Na v 1.5 in striated muscle where dystrophin is normally abundant, our results suggest that it could be important in tissues where the composition of the DMC is altered, for instance when dystrophin is absent because mutation of its gene, or decreased in failing hearts. 35 
Utrophin up-regulation in hearts of mdx5cv mice
The mdx mouse is the most widely used animal model for DMD.
The mdx mouse lacks dystrophin as a result of a point mutation in exon 23 of the dystrophin gene, forming a premature stop codon. 36 However, 'revertant' dystrophin-positive cells have been reported in these mice. 37 The mdx5cv mouse, generated by N-ethyl N-nitrosourea mutagenesis, also lacks full length dystrophin and does not display revertant cells. Cardiac up-regulation of utrophin has been reported in different animal models lacking full length dystrophin, such as human, hamster, and the mdx mouse, 17 -19 but utrophin over-expression in the hearts of mdx5cv mice has not been previously reported. We provide evidence that the up-regulation of utrophin also occurs in mdx5cv mice. In order to verify that the decrease in functional Na v 1.5 found in mdx5cv was not strain-specific, we assessed the sodium peak current in mdx mice. We found a decrease similar to that previously observed in mdx5cv, 11 suggesting that down-regulation of the channel in the absence of dystrophin is a general phenomenon in mice and occurs despite utrophin over-expression. 4.3 Consequences of decreased Na v 1.5 protein and sodium current in DKO mice
We found that deletion of the SIV motif of Na v 1.5, abolishing its interaction with the syntrophin proteins, leads to a decrease in the expression of the channel in HEK293 cells. Moreover, we found that utrophin deletion in mdx mice leads to a strong reduction in the Na v 1.5 protein and sodium peak current. A similar decrease in syntrophins was concomitantly observed, suggesting that the two proteins may belong to the same complex and have a similar fate in the absence of dystrophin or utrophin. This observation raises the question of the role of the DMC in the stabilization of sodium channels at the sarcolemma. Further investigations will be needed to determine whether targeting or anchoring of these two proteins is altered when dystrophin and utrophin are absent. DKO mice are considered to be a more appropriate model of human dystrophies than mdx mice as they display most of the clinical signs of DMD, including short stature, kyphosis, hindlimb weakness, laboured breathing, and premature death. 36 In addition, cardiac complications in DKO mice are similar to those seen in DMD patients. DKO mice exhibit abnormal ECG patterns with drastically decreased S-to-R wave ratios, a feature observed in 70 -80% of the DMD patients. 38, 39 However, conduction defects have not been reported as a prominent feature neither in DKO mice nor in DMD patients. As conduction defects are progressive in DMD 40 and in SCN5A-related animal models 41, 42 despite an important decrease in I Na from birth on, one may speculate that the age-dependent conduction defect phenotypes observed in sodium-channel-related pathologies are the result of subsequent remodelling processes involving fibrotic changes and connexin proteins remodelling as observed by van Veen et al. 43 In the present study, we found a 40% decrease in the peak sodium current in the cardiomyocytes of DKO mice when compared with mdx mice. Similar to results obtained by Leoni et al., 42 we also observed that the loss of Na v 1.5 proteins and current promotes significant shifts towards more positive voltages of steady-state inactivation and activation curves, increasing the fraction of sodium channels available for cardiac depolarization in DKO mice when compared with mdx mice. Molecular and cellular mechanisms altering the biophysical properties of Na v 1.5 when channel quantity is decreased remain to be investigated. The strong reduction in the sodium current of DKO cardiomyocytes is reflected by a significant slowing of the AP maximal upstroke velocity, considered as a suitable index for the estimation of available functional sodium channels. The maximal upstroke velocity has been shown to slightly overestimate peak I Na at slowed AP upstrokes, 44 consistent with the relative decreases in I Na and (dV/dt) max in DKO cardiomyocytes observed in this study. In a previous study, we have shown that the decrease of 30% in I Na observed in mdx5cv mice compared with C57BL/6J mice is associated with an increase of 18% of the QRS complex duration in these mice. 11 Interestingly, these values are in very good agreement with the predictions by Shaw and Rudy 45 on the influence of reduced maximal sodium conductance on conduction velocity. Quantitatively, we would estimate that the reduction of another 40% in I Na observed in the present study between mdx and DKO would result in further ventricular conduction slowing of 15 -20%. The importantly reduced I Na in DKO hearts thus probably partially underlies the drastic difference in phenotype between DKO and mdx. However, other proteins such as inducible nitric oxide synthase or neuronal nitric oxide synthase have also been shown to be modified in the combined absence of both dystrophin and utrophin. 38 Moreover, cellular pathways known to be affected in the absence of dystrophin would be expected to be more severe when utrophin is also absent. For instance, the amplification of Ca 2+ -and reactive oxygen species-dependent degradative pathways in dystrophin-deficient cardiomyocytes 46 are most likely limited by the presence and up-regulation of utrophin in mdx mice and would thus be expected to contribute to the drastic phenotype in DKO mice. In conclusion, the difference in phenotype between mdx and DKO mice is likely the sum of several cellular modifications, including alteration of the sodium current.
Relevance for human cardiomyopathies
Different types of cardiomyopathies are the underlying cause of death in up to 20% of individuals with DMD, a proportion that is likely to increase over the coming years. 4 With ventilatory support preventing respiratory-related mortality, most DMD patients will survive into their third decade, in which incidence of cardiomyopathies is nearly 100%. 47 We previously reported on the importance of dystrophin in the regulation of the Na v 1.5 protein and its current. In this study, we demonstrate that the sodium channel phenotype observed in mdx mice is likely limited by the up-regulation of utrophin. This suggests that an increased up-regulation of utrophin could, in principle, restore more functional sodium channels, supporting current therapeutic strategies aimed at treating DMDs through the overexpression of endogenous utrophin. 15 Compared with other approaches such as gene or cell therapy that targets exogenous dystrophin expression, 48 pharmacological strategies designed to overexpress utrophin are promising and may circumvent many obstacles inherent to gene and cell-based therapies such as adverse immune response. 49, 50 In this study, we provide additional evidence that the over-expression of utrophin could have a positive outcome in the absence of dystrophin and could provide a means to treat cardiomyopathy in dystrophic patients by restoring the amount and integrity of proteins of the DMC, as is the case for Na v 1.5. In summary, our study provides evidence that up-regulation of utrophin in the hearts of mdx mice counteracts the reduction in Na v 1.5 protein levels and sodium current. Utrophin deletion in these mice leads to a severe reduction in channel protein expression and to the subsequent decrease in the sodium peak current amplitude and maximal upstroke velocity of the AP. It is clear that the regulatory role of utrophin on Na v 1.5 may also be mediated by syntrophin as suggested by its concomitant decrease with the sodium channel in utrophin-deficient tissue. Altogether, these findings strongly argue in favour of the development of therapeutic strategies aimed at utrophin up-regulation to treat cardiac alterations in DMD.
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